| 0 |
ANAL GONOCOCCAL INFECTION |
2 |
0.5000 |
| 1 |
OROPHARYNGEAL GONOCOCCAL INFECTION |
1 |
0.0370 |
| 2 |
INJECTION SITE DISCHARGE |
149 |
0.0277 |
| 3 |
ADMINISTRATION SITE WOUND |
2 |
0.0202 |
| 4 |
ADMINISTRATION SITE DISCHARGE |
1 |
0.0172 |
| 5 |
APPENDICITIS NONINFECTIVE |
1 |
0.0167 |
| 6 |
INJECTION SITE NODULE |
113 |
0.0103 |
| 7 |
INJECTION SITE CELLULITIS |
17 |
0.0091 |
| 8 |
URETHRAL DISCHARGE |
1 |
0.0082 |
| 9 |
PERINEAL RASH |
1 |
0.0081 |
| 10 |
INJECTION SITE MOVEMENT IMPAIRMENT |
1 |
0.0078 |
| 11 |
INJECTION SITE ULCER |
7 |
0.0074 |
| 12 |
LIPOSUCTION |
1 |
0.0065 |
| 13 |
ABDOMINAL WALL WOUND |
1 |
0.0065 |
| 14 |
PRODUCT ADMINISTRATION ISSUE |
1 |
0.0048 |
| 15 |
INJECTION SITE NERVE DAMAGE |
1 |
0.0042 |
| 16 |
FOREIGN BODY REACTION |
1 |
0.0041 |
| 17 |
ACUTE HIV INFECTION |
1 |
0.0040 |
| 18 |
SELF-CONSCIOUSNESS |
1 |
0.0039 |
| 19 |
INJECTION SITE PARAESTHESIA |
6 |
0.0039 |
| 20 |
GONORRHOEA |
1 |
0.0037 |
| 21 |
HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION |
1 |
0.0036 |
| 22 |
HIV TEST POSITIVE |
2 |
0.0030 |
| 23 |
BODY DYSMORPHIC DISORDER |
1 |
0.0027 |
| 24 |
INJECTION SITE PUSTULE |
1 |
0.0026 |
| 25 |
PRODUCT ADMINISTERED BY WRONG PERSON |
1 |
0.0026 |
| 26 |
INJECTION SITE ABSCESS |
6 |
0.0024 |
| 27 |
INJECTION SITE INFECTION |
7 |
0.0021 |
| 28 |
INJECTION SITE HYPOAESTHESIA |
3 |
0.0021 |
| 29 |
PALATAL DISORDER |
1 |
0.0017 |
| 30 |
SERUM SICKNESS-LIKE REACTION |
1 |
0.0016 |
| 31 |
NASAL CRUSTING |
1 |
0.0015 |
| 32 |
SOFT TISSUE NECROSIS |
1 |
0.0015 |
| 33 |
SYPHILIS |
1 |
0.0014 |
| 34 |
INJECTION SITE INFLAMMATION |
5 |
0.0010 |
| 35 |
INJECTION SITE MASS |
37 |
0.0010 |
| 36 |
GENOTYPE DRUG RESISTANCE TEST POSITIVE |
1 |
0.0010 |
| 37 |
INJECTION SITE DISCOMFORT |
10 |
0.0009 |
| 38 |
INCISION SITE PAIN |
1 |
0.0009 |
| 39 |
INJECTION SITE HYPERSENSITIVITY |
2 |
0.0006 |
| 40 |
PAPILLOMA VIRAL INFECTION |
1 |
0.0006 |
| 41 |
SEIZURE LIKE PHENOMENA |
1 |
0.0006 |
| 42 |
BLOOD CHOLESTEROL DECREASED |
1 |
0.0005 |
| 43 |
EARLY SATIETY |
1 |
0.0005 |
| 44 |
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME |
1 |
0.0005 |
| 45 |
INJECTION SITE NECROSIS |
1 |
0.0005 |
| 46 |
INJECTION SITE PAIN |
141 |
0.0005 |
| 47 |
INCORRECT ROUTE OF PRODUCT ADMINISTRATION |
7 |
0.0004 |
| 48 |
TENDERNESS |
4 |
0.0004 |
| 49 |
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE |
7 |
0.0004 |
| 50 |
ABDOMINAL MASS |
1 |
0.0004 |
| 51 |
PRESYNCOPE |
9 |
0.0004 |
| 52 |
HYPOMENORRHOEA |
1 |
0.0004 |
| 53 |
INJECTION SITE ERYTHEMA |
43 |
0.0003 |
| 54 |
INJECTION SITE IRRITATION |
4 |
0.0003 |
| 55 |
INJECTION SITE SWELLING |
24 |
0.0003 |
| 56 |
INJECTION SITE INDURATION |
4 |
0.0003 |
| 57 |
EYE MOVEMENT DISORDER |
2 |
0.0003 |
| 58 |
HYPERTRANSAMINASAEMIA |
2 |
0.0003 |
| 59 |
ERYTHEMA NODOSUM |
1 |
0.0003 |
| 60 |
PYODERMA GANGRENOSUM |
1 |
0.0003 |
| 61 |
RECTAL DISCHARGE |
1 |
0.0003 |
| 62 |
VIRAL LOAD INCREASED |
1 |
0.0003 |
| 63 |
INJECTION SITE WARMTH |
5 |
0.0002 |
| 64 |
INJECTION SITE DISCOLOURATION |
3 |
0.0002 |
| 65 |
PRODUCT DISPENSING ISSUE |
1 |
0.0002 |
| 66 |
NODULE |
3 |
0.0002 |
| 67 |
BRAIN NEOPLASM MALIGNANT |
1 |
0.0002 |
| 68 |
INJECTION SITE PAPULE |
1 |
0.0002 |
| 69 |
YELLOW SKIN |
1 |
0.0002 |
| 70 |
VIRAL UPPER RESPIRATORY TRACT INFECTION |
1 |
0.0002 |
| 71 |
GUILLAIN-BARRE SYNDROME |
1 |
0.0002 |
| 72 |
INJECTION SITE REACTION |
14 |
0.0002 |
| 73 |
ABDOMINAL TENDERNESS |
1 |
0.0002 |
| 74 |
PRODUCT COLOUR ISSUE |
1 |
0.0002 |
| 75 |
INJECTION SITE BRUISING |
15 |
0.0002 |
| 76 |
FOOD POISONING |
1 |
0.0002 |
| 77 |
NONSPECIFIC REACTION |
1 |
0.0002 |
| 78 |
GASTROINTESTINAL PAIN |
2 |
0.0002 |
| 79 |
SKIN WARM |
1 |
0.0002 |
| 80 |
INJECTION SITE VESICLES |
1 |
0.0002 |
| 81 |
PROCTALGIA |
1 |
0.0002 |
| 82 |
PRODUCT PREPARATION ISSUE |
1 |
0.0002 |
| 83 |
SKIN MASS |
1 |
0.0001 |
| 84 |
PRODUCT LABEL ISSUE |
1 |
0.0001 |
| 85 |
ACCIDENTAL UNDERDOSE |
2 |
0.0001 |
| 86 |
INTENTIONAL UNDERDOSE |
1 |
0.0001 |
| 87 |
PAROSMIA |
1 |
0.0001 |
| 88 |
INTERCEPTED PRODUCT ADMINISTRATION ERROR |
1 |
0.0001 |
| 89 |
SYNCOPE |
13 |
0.0001 |
| 90 |
PRODUCT ADMINISTRATION INTERRUPTED |
1 |
0.0001 |
| 91 |
LOSS OF CONSCIOUSNESS |
16 |
0.0001 |
| 92 |
UPPER-AIRWAY COUGH SYNDROME |
1 |
0.0001 |
| 93 |
PRODUCT COMMUNICATION ISSUE |
1 |
0.0001 |
| 94 |
INJECTION SITE HAEMORRHAGE |
9 |
0.0001 |
| 95 |
DEFORMITY |
1 |
0.0001 |
| 96 |
RECALLED PRODUCT ADMINISTERED |
1 |
0.0001 |
| 97 |
CYTOPENIA |
1 |
0.0001 |
| 98 |
INJECTION SITE PRURITUS |
5 |
0.0001 |
| 99 |
TACHYPNOEA |
1 |
0.0001 |
| 100 |
MASS |
1 |
0.0001 |
| 101 |
URINARY INCONTINENCE |
2 |
0.0001 |
| 102 |
HIP ARTHROPLASTY |
1 |
0.0001 |
| 103 |
INJECTION SITE RASH |
2 |
0.0001 |
| 104 |
DELUSION |
1 |
0.0001 |
| 105 |
PRODUCT USE COMPLAINT |
1 |
0.0001 |
| 106 |
SENSORY DISTURBANCE |
1 |
0.0001 |
| 107 |
MOVEMENT DISORDER |
2 |
0.0001 |
| 108 |
NIGHT SWEATS |
2 |
0.0001 |
| 109 |
MUSCLE TIGHTNESS |
1 |
0.0001 |
| 110 |
PRODUCT STORAGE ERROR |
5 |
0.0001 |
| 111 |
COLD SWEAT |
1 |
0.0001 |
| 112 |
LYMPHADENOPATHY |
2 |
0.0001 |
| 113 |
MUSCULOSKELETAL DISORDER |
1 |
0.0001 |
| 114 |
FEELING JITTERY |
1 |
0.0001 |
| 115 |
CHOKING |
1 |
0.0001 |
| 116 |
ORAL HERPES |
1 |
0.0001 |
| 117 |
CYTOKINE RELEASE SYNDROME |
1 |
0.0000 |
| 118 |
EXTRA DOSE ADMINISTERED |
2 |
0.0000 |
| 119 |
BODY TEMPERATURE INCREASED |
1 |
0.0000 |
| 120 |
IMPAIRED WORK ABILITY |
1 |
0.0000 |
| 121 |
HYPERHIDROSIS |
6 |
0.0000 |
| 122 |
RASH PAPULAR |
1 |
0.0000 |
| 123 |
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS |
9 |
0.0000 |
| 124 |
SWELLING |
4 |
0.0000 |
| 125 |
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES |
2 |
0.0000 |
| 126 |
NEURALGIA |
1 |
0.0000 |
| 127 |
CELLULITIS |
2 |
0.0000 |
| 128 |
ERECTILE DYSFUNCTION |
1 |
0.0000 |
| 129 |
UNRESPONSIVE TO STIMULI |
1 |
0.0000 |
| 130 |
MUSCLE SPASMS |
7 |
0.0000 |
| 131 |
ANHEDONIA |
1 |
0.0000 |
| 132 |
JAUNDICE |
1 |
0.0000 |
| 133 |
BLOOD BILIRUBIN INCREASED |
1 |
0.0000 |
| 134 |
PALLOR |
1 |
0.0000 |
| 135 |
WOUND |
1 |
0.0000 |
| 136 |
PRODUCT DOSE OMISSION IN ERROR |
1 |
0.0000 |
| 137 |
SEIZURE |
4 |
0.0000 |
| 138 |
NEEDLE ISSUE |
1 |
0.0000 |
| 139 |
DYSSTASIA |
1 |
0.0000 |
| 140 |
CHILLS |
4 |
0.0000 |
| 141 |
SURGERY |
2 |
0.0000 |
| 142 |
MATERNAL EXPOSURE DURING PREGNANCY |
3 |
0.0000 |
| 143 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
6 |
0.0000 |
| 144 |
DISCOMFORT |
2 |
0.0000 |
| 145 |
HEAD INJURY |
1 |
0.0000 |
| 146 |
CHOLELITHIASIS |
1 |
0.0000 |
| 147 |
VIRAL INFECTION |
1 |
0.0000 |
| 148 |
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR |
1 |
0.0000 |
| 149 |
MYALGIA |
5 |
0.0000 |
| 150 |
RESTLESSNESS |
1 |
0.0000 |
| 151 |
EYE SWELLING |
1 |
0.0000 |
| 152 |
UNEVALUABLE EVENT |
2 |
0.0000 |
| 153 |
PALPITATIONS |
3 |
0.0000 |
| 154 |
VOMITING |
12 |
0.0000 |
| 155 |
DISORIENTATION |
1 |
0.0000 |
| 156 |
OSTEOPOROSIS |
1 |
0.0000 |
| 157 |
TREMOR |
4 |
0.0000 |
| 158 |
RHABDOMYOLYSIS |
1 |
0.0000 |
| 159 |
CARDIO-RESPIRATORY ARREST |
1 |
0.0000 |
| 160 |
URTICARIA |
4 |
0.0000 |
| 161 |
SKIN EXFOLIATION |
2 |
0.0000 |
| 162 |
MENTAL DISORDER |
1 |
0.0000 |
| 163 |
INTENTIONAL PRODUCT USE ISSUE |
2 |
0.0000 |
| 164 |
INCORRECT DOSE ADMINISTERED |
5 |
0.0000 |
| 165 |
ABDOMINAL PAIN |
5 |
0.0000 |
| 166 |
PRODUCT USE ISSUE |
4 |
0.0000 |
| 167 |
GAIT DISTURBANCE |
4 |
0.0000 |
| 168 |
DIZZINESS |
10 |
0.0000 |
| 169 |
THERAPY CESSATION |
1 |
0.0000 |
| 170 |
ABDOMINAL PAIN UPPER |
4 |
0.0000 |
| 171 |
ABDOMINAL DISTENSION |
2 |
0.0000 |
| 172 |
DRUG INTERACTION |
3 |
0.0000 |
| 173 |
RASH PRURITIC |
1 |
0.0000 |
| 174 |
ABDOMINAL DISCOMFORT |
3 |
0.0000 |
| 175 |
PRODUCT SUBSTITUTION ISSUE |
1 |
0.0000 |
| 176 |
PYREXIA |
6 |
0.0000 |
| 177 |
NASAL CONGESTION |
1 |
0.0000 |
| 178 |
STOMATITIS |
1 |
0.0000 |
| 179 |
PRODUCT USE IN UNAPPROVED INDICATION |
4 |
0.0000 |
| 180 |
RHINORRHOEA |
1 |
0.0000 |
| 181 |
NAUSEA |
12 |
0.0000 |
| 182 |
PAIN |
9 |
0.0000 |
| 183 |
THERAPY INTERRUPTED |
1 |
0.0000 |
| 184 |
HYPOAESTHESIA |
2 |
0.0000 |
| 185 |
HALLUCINATION |
1 |
0.0000 |
| 186 |
HOT FLUSH |
1 |
0.0000 |
| 187 |
BACK PAIN |
3 |
0.0000 |
| 188 |
INFLUENZA LIKE ILLNESS |
1 |
0.0000 |
| 189 |
INSOMNIA |
3 |
0.0000 |
| 190 |
TACHYCARDIA |
1 |
0.0000 |
| 191 |
NO ADVERSE EVENT |
2 |
0.0000 |
| 192 |
SUICIDAL IDEATION |
1 |
0.0000 |
| 193 |
NASOPHARYNGITIS |
2 |
0.0000 |
| 194 |
OROPHARYNGEAL PAIN |
1 |
0.0000 |
| 195 |
BREAST CANCER |
1 |
0.0000 |
| 196 |
ANXIETY |
3 |
0.0000 |
| 197 |
CONTUSION |
1 |
0.0000 |
| 198 |
SOMNOLENCE |
2 |
0.0000 |
| 199 |
SINUSITIS |
1 |
0.0000 |
| 200 |
ERYTHEMA |
2 |
0.0000 |
| 201 |
HEADACHE |
6 |
0.0000 |
| 202 |
INFLUENZA |
1 |
0.0000 |
| 203 |
DECREASED APPETITE |
2 |
0.0000 |
| 204 |
PRURITUS |
3 |
0.0000 |
| 205 |
DRY SKIN |
1 |
0.0000 |
| 206 |
PRODUCT QUALITY ISSUE |
1 |
0.0000 |
| 207 |
ARTHRALGIA |
3 |
0.0000 |
| 208 |
DYSPNOEA |
4 |
0.0000 |
| 209 |
PRODUCT DOSE OMISSION ISSUE |
2 |
0.0000 |
| 210 |
PAIN IN EXTREMITY |
2 |
0.0000 |
| 211 |
ACUTE KIDNEY INJURY |
1 |
0.0000 |
| 212 |
CEREBROVASCULAR ACCIDENT |
1 |
0.0000 |
| 213 |
HYPERSENSITIVITY |
1 |
0.0000 |
| 214 |
FATIGUE |
4 |
0.0000 |
| 215 |
HYPOTENSION |
1 |
0.0000 |
| 216 |
DIARRHOEA |
3 |
0.0000 |
| 217 |
RASH |
2 |
0.0000 |
| 218 |
OFF LABEL USE |
4 |
0.0000 |
| 219 |
DEPRESSION |
1 |
0.0000 |
| 220 |
FEELING ABNORMAL |
1 |
0.0000 |
| 221 |
COUGH |
1 |
0.0000 |
| 222 |
CONDITION AGGRAVATED |
1 |
0.0000 |
| 223 |
ASTHENIA |
1 |
0.0000 |
| 224 |
DRUG INEFFECTIVE |
2 |
0.0000 |